{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:08:30Z","timestamp":1790780910687,"version":"4.1.0"},"reference-count":99,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2016.00428","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T03:17:45Z","timestamp":1478661465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma"],"prefix":"10.3389","volume":"7","author":[{"given":"Massimiliano","family":"Berretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arben","family":"Lleshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vall\u00ec","family":"De Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Di Francia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/jco.2014.32.3_suppl.286","article-title":"Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) [Abstract]","volume":"32","author":"Abou-Alfa","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1535-7163.MCT-05-0410","article-title":"Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor","volume":"5","author":"Albert","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/COC.0b013e3182118cdf","article-title":"Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II north central cancer treatment group clinical trial","volume":"35","author":"Alberts","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/1751-2980.12038","article-title":"Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study","volume":"14","author":"Bai","year":"2013","journal-title":"J. Dig. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.2174\/18715206113136660350","article-title":"Colorectal cancer in elderly patients: from best supportive care to cure","volume":"13","author":"Berretta","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"B6","first-page":"e558","article-title":"New entities in the treatment of hepatocellular carcinoma: HIV-positive and elderly patients","volume":"2","author":"Berretta","year":"2015a","journal-title":"WCRJ"},{"key":"B7","first-page":"e133","article-title":"Editorial\u2013The new oncologic challenges in the 3rd millennium","volume":"1","author":"Berretta","year":"2014","journal-title":"WCRJ"},{"key":"B8","first-page":"2521","article-title":"Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma","volume":"19","author":"Berretta","year":"2015b","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1634\/theoncologist.2010-0400","article-title":"Hepatocellular carcinoma in HIV-infected patients: check early, treat hard","volume":"16","author":"Berretta","year":"2011","journal-title":"Oncologist"},{"key":"B10","first-page":"3619","article-title":"Clinical presentation and outcome of non-AIDS defining cancer, in HIV-infected patients in the ART-era:the Italian Cooperative Group on AIDS and tumors activity","volume":"19","author":"Berretta","year":"2015c","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B11","first-page":"e561","article-title":"Primary liver cancer: clinical aspects, prognostic factors and predictive response to therapy","volume":"2","author":"Berretta","year":"2015","journal-title":"WCRJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/gutjnl-2013-306627","article-title":"Hepatocellular carcinoma: clinical frontiers and perspectives","volume":"63","author":"Bruix","year":"2014a","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/jco.2014.32.15_suppl.4006","article-title":"STORM Investigators. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) [Abstract]","volume":"32","author":"Bruix","year":"2014b","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.27859","article-title":"Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"119","author":"Buijs","year":"2013","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1021\/jm7013309","article-title":"Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)","volume":"51","author":"Cai","year":"2008","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B19","first-page":"e485","article-title":"Hepatocellular carcinoma: an overvierw of clinic-pathological and molecular prespectives","volume":"2","author":"Canzonieri","year":"2015","journal-title":"WCRJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.4161\/cc.21193","article-title":"Molecular mechanisms of sorafenib action in liver cancer cells","volume":"11","author":"Cervello","year":"2012","journal-title":"Cell Cycle"},{"key":"B21","first-page":"e490","article-title":"Liver resection for HCC in HIV-infected patients: a single center experience","volume":"2","author":"D'Amico","year":"2015a","journal-title":"WCRJ"},{"key":"B22","first-page":"e490","article-title":"Isolated caudate lobectomy for Spiegel lobe neoplasms","volume":"2","author":"D'Amico","year":"2015b","journal-title":"WCRJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"GRID study investigators. GRID study investigators. Efficacy and safety of regorafenib for advanced gastroin inal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"B24","first-page":"e276","article-title":"Pharmacogenomics markers for prediction response and toxicity in cancer therapy","volume":"1","author":"De Monaco","year":"2014","journal-title":"WCRJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jso.22039","article-title":"Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadiuvant approach plus m-TOR inhibitors monotherapy?","volume":"105","author":"Di Benedetto","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ejso.2007.05.004","article-title":"Hepatocellular carcinoma in HIV patients treated by liver transplsntation","volume":"34","author":"Di Benedetto","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2012-0255","article-title":"Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients","volume":"18","author":"Di Benedetto","year":"2013b","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1111\/j.1432-2277.2011.01329.x","article-title":"Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up","volume":"24","author":"Di Benedetto","year":"2011","journal-title":"Transpl. Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2174\/18715206113136660342","article-title":"Hepatocellular carcinoma: beyond the boundaries of age","volume":"13","author":"Di Benedetto","year":"2013a","journal-title":"Anticancer Agents Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/radiol.13131305","article-title":"Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial","volume":"271","author":"Ellingson","year":"2014","journal-title":"Radiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18632\/oncotarget.763","article-title":"Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer","volume":"4","author":"Falchook","year":"2013","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","article-title":"Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma","volume":"18","author":"Finn","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jhep.2013.07.029","article-title":"Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma","volume":"59","author":"Finn","year":"2013","journal-title":"J. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"REGARD trial investigators. REGARD trial investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomized, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4254\/wjh.v8.i16.665","article-title":"Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis","volume":"8","author":"Garbuzenko","year":"2016","journal-title":"World J. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/hepr.12663","article-title":"Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma","volume":"46","author":"Hirotsu","year":"2016","journal-title":"Hepatol. Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1158\/1078-0432.CCR-05-2225","article-title":"New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer","volume":"12","author":"Hong","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/sj.bjc.6605580","article-title":"Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"102","author":"Hsu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1158\/1078-0432.CCR-08-0509","article-title":"Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma","volume":"14","author":"Huynh","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"REDA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK 1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1586\/17474124.2015.959929","article-title":"Evolution from WHO to EASL and RECIST for hepatocellular carcinoma: considerations for tumor response assessment","volume":"9","author":"Kim","year":"2015","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/BJ20110301","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"437","author":"Koch","year":"2011","journal-title":"Biochem. J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.2174\/138161212800626166","article-title":"Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer","volume":"18","author":"Korpanty","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.3748\/wjg.v22.i30.6841","article-title":"Cancer-associated fibroblasts in hepatocellular carcinoma","volume":"22","author":"Kubo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-2755","article-title":"Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo","volume":"17","author":"Kudo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1158\/1078-0432.CCR-13-3445","article-title":"A phase II study of the efficacy and safety of the combination therapy of MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma","volume":"20","author":"Lim","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrclinonc.2014.136","article-title":"Liver cancer: time to evolve trial desi gn after everolimus failure","volume":"11","author":"Llovet","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for phase 3 failure and novel perspectives on trial design","volume":"20","author":"Llovet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1055\/s-0034-1394365","article-title":"Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation","volume":"34","author":"Mazzaferro","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angioprotein therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomized, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1245\/s10434-010-1310-y","article-title":"Tyrosine kinase inhibitor PTK\/ZK enhances the antitumor effects of interferon-\u03b1\/5-fluorouracil therapy for hepatocellular carcinoma cells","volume":"18","author":"Murakami","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"B60","first-page":"1257","article-title":"Hepatocellular carcinoma in HIV positive patients","volume":"16","author":"Nunnari","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-10-2011","article-title":"Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Park","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"Pawlik","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","article-title":"Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma","volume":"10","author":"Piguet","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/PPO.0b013e3181c5214b","article-title":"Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States","volume":"15","author":"Reyes","year":"2009","journal-title":"Cancer J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"B67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1871520614666140902153840","article-title":"A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib","volume":"15","author":"Roy","year":"2015","journal-title":"Anticancer Agents Med. Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebocontrolled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1593\/neo.13812","article-title":"Allosteric MEK l\/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits anti tumor activity in preclinical murine and rat models of hepatocellular carcinoma","volume":"15","author":"Schmieder","year":"2013","journal-title":"Neoplasia"},{"key":"B71","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","article-title":"Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis","volume":"312","author":"Shibuya","year":"2006","journal-title":"Exp. Cell Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/13543784.2012.684752","article-title":"Regorafenib for cancer","volume":"21","author":"Strumberg","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/cncr.25889","article-title":"Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma","volume":"117","author":"Sun","year":"2011","journal-title":"Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2014.03.017","article-title":"Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity","volume":"61","author":"Tai","year":"2014","journal-title":"J. Hepatol."},{"key":"B76","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1074\/jbc.271.2.603","article-title":"Vascular endothelial grouth factor, a potent and selective angiogenic agents","volume":"271","author":"Thomas","year":"1996","journal-title":"J. Biol. Chem."},{"key":"B77","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/cncr.27758","article-title":"Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma","volume":"119","author":"Toh","year":"2013","journal-title":"Cancer"},{"key":"B79","first-page":"1599","article-title":"Radiotherapy and hepatocellular carcinoma: update and review of literature","volume":"16","author":"Ursino","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics","volume":"46","author":"Varela","year":"2007","journal-title":"J. Hepatol."},{"key":"B81","first-page":"203","article-title":"Regulation of angiogenesis via vascular endothelial growth factor receptors","volume":"60","author":"Veikkola","year":"2000","journal-title":"Cancer Res."},{"key":"B82","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/jco.2012.30.15_suppl.4007","article-title":"Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT) [Abstract]","volume":"30","author":"Verslype","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"B83","first-page":"189","article-title":"Regulation of signaling events involved in the pathophysiology of neovascular AMD","volume":"22","author":"Wang","year":"2016","journal-title":"Mol. Vis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"RAINBOW Study Group. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"B85","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1002\/cncr.25372","article-title":"Phase 1-2 trial of PTK787\/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma","volume":"116","author":"Yau","year":"2010","journal-title":"Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/08941939.2010.542272","article-title":"Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells","volume":"24","author":"Yi","year":"2011","journal-title":"J. Invest. Surg."},{"key":"B89","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jhep.2004.03.001","article-title":"Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development","volume":"41","author":"Yoshiji","year":"2004","journal-title":"J. Hepatol."},{"key":"B90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1665-2681(19)30803-8","article-title":"Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration","volume":"14","author":"Zampino","year":"2015","journal-title":"Ann. Hepatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/annonc\/mdt072","article-title":"Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients","volume":"24","author":"Zhao","year":"2013","journal-title":"Ann. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1634\/theoncologist.11-7-790","article-title":"Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?","volume":"11","author":"Zhu","year":"2006","journal-title":"Oncologist"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-12-3041","article-title":"Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"19","author":"Zhu","year":"2013a","journal-title":"Clin. Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","article-title":"HCC and angiogenesis: possible targets and future directions","volume":"8","author":"Zhu","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-13-1442","article-title":"A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer","volume":"19","author":"Zhu","year":"2013b","journal-title":"Clin. Cancer Res."},{"key":"B97","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/jco.2014.32.3_suppl.172","article-title":"EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib [Abstract]","volume":"32","author":"Zhu","year":"2014a","journal-title":"J. Clin. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014b","journal-title":"JAMA"},{"key":"B99","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/jco.2015.33.3_suppl.232","article-title":"Ramucirumab (RAM) a second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated \u03b1-fetoprotein (AFP) from the randomized phase III REACH study [abstract]","volume":"33","author":"Zhu","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2016.00428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T05:49:04Z","timestamp":1601185744000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2016.00428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,9]]},"references-count":99,"URL":"https:\/\/doi.org\/10.3389\/fphar.2016.00428","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,9]]}}}